Pharvaris N.V. (PHVS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Core Proposition - Deucrictibant offers an oral therapy option that addresses a specific unmet need in the treatment of hereditary angioedema (HAE) [2] - The preference for oral therapies among patients is high, indicating a demand for more convenient treatment options that enhance normalcy in patients' lives [2] - Efficacy remains the paramount proposition for any therapy, particularly in the context of HAE [2][3] Treatment Aspects - The oral formulation of deucrictibant is a key feature, but the company emphasizes that efficacy is equally important [2] - The combination of an oral delivery method with high efficacy is a significant aspect of the product's value proposition [3]